Merck/Banyu: A Harbinger of More Western-Japanese Deals?
Executive Summary
It's now official: the Japanese drug industry is succumbing to consolidation. The only question is whether the consolidators will be Western companies or the Japanese themselves. The latest and least unexpected transaction: Merck & Co. Inc.'s takeover of the remaining 49% of Banyu Pharmaceutical Co. Ltd. it didn't already own, in a $1.52 billion tender offer.
You may also be interested in...
The Rise Of Japanese Pharma Dealmakers
Japanese pharmas are now serious contenders for partnerships outside their home country, increasing their spending on both alliances and acquisitions in recent years. The increased desire to partner with Western biotechs is good news for smaller industry players as the recent spate of mega-mergers has resulted in a smaller pool of potential acquirers for their assets.IN VIVO presents an analysis of recent trends in biopharmaceutical dealmaking between Japan and the West.
Trends in Japanese Alliances
As consolidation pressures wrack the Japanese pharmaceutical industry some retrenchment in Japanese inlicensing has followed. We examine recent trends in Japanese licensing.
Trends in Japanese Alliances
As consolidation pressures wrack the Japanese pharmaceutical industry some retrenchment in Japanese inlicensing has followed. We examine recent trends in Japanese licensing.